Glofitamab (Columvi®) as monotherapy for the treatment of relapsed or refractory (R/R) diffuse large B‑cell lymphoma (DLBCL). Update February 2024

Rothschedl, E. and Grössmann, N. (2023): Glofitamab (Columvi®) as monotherapy for the treatment of relapsed or refractory (R/R) diffuse large B‑cell lymphoma (DLBCL). Update February 2024. Fact Sheet Nr. 130.

[thumbnail of Fact Sheet Nr.130_2nd Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
139kB

Item Type:	Horizon Scanning of Medicines
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WH Hemic and lymphatic systems
Language:	English
Series Name:	Fact Sheet Nr. 130
Deposited on:	25 May 2023 11:47
Last Modified:	10 Jul 2025 11:37

Repository Staff Only: item control page